We are your partner for visionary steps forward. We imagine and invest for a more healthy future. We are fanatically devoted to excellence. We know peaks and valleys. We only collaborate with true entrepreneurs.

Building
great businesses

We are privately owned by Dr. Werner Lanthaler. Wlanholding is your partner for visionary steps forward. We are committed to driving innovation and sustainable growth in cutting-edge technologies, clearly focusing on high tech life science and sustainability investments. With our strong and broad investment portfolio we imagine and invest most importantly for a healthier future.

Making smart businesses truly scalable. Longterm.

At WLan our focus is your business! We act as entrepreneurial partner, offering hands-on experience and a down-to-earth approach. We are committed to support passionate founders and management teams to reach the next critical stage of growth, transforming smart and innovative businesses into scalable organizations. On this journey, we frame visions, expand horizons, and open doors by bringing in our ample experience in growth financings, IPOs and M&As. Our investment is long term, the value created substantial – quick exits are not on our list, we love long term impact!

A blend of best-in class expertise.
With a dedicated team and wide networks.

Meet Our Founder:
Dr. Werner Lanthaler

Dr. Werner Lanthaler is the Founder and CEO of Wlanholding, a family office dedicated to investments and advisory services in life science and high-tech sustainability companies. Our recent key investments include: Proxygen GmbH, Cerabyte GmbH, Solgate GmbH, Planet Pure GmbH, Cyment GmbH and Pexxes GmbH. WLan typically is an active investor and advisor.  Together with a dedicated team of associated partners we provide top class expertise for due diligence, or the entrepre­neurial built of all business functions.

Read more

Driving Growth.
Devoted to excellence.

WLan is an active investor, closely collaborating with founders and key management to drive substantial growth. In our investment strategy we focus only on transformative technologies in two megatrends: high-tech life science and high-tech driven sustainability. We love to follow our initial investments, and offer “Angel” seed capital and high tech growth capital, with a view to invest at least up to “Series B”.

Sector Focus

  • • High-tech life science
  • • High-tech driven sustainability

Strategies

  • • „Angel“ seed capital
  • • High-tech growth capital

We bring valuable technology translation and transaction expertise to both. Led by Werner Lanthaler, our combined knowledge is based on many years of hands-on experience and is backed by four successfully completed IPOs and over 15 M&A transactions.

WLan

Deep partnership
with founders &
management

Best in class
governance &
culture support

Branding,
business building &
marketing platform

Funding, M&A
and exit support
strategies

´

Portfolio Highlights

Over the past decade we have successfully completed more than 10 high-tech life science and sustainability investments. Highlights include ALAS and allcyte.

Building better
businesses

At WLan we are building a diverse portfolio of innovative, high-growth companies, each working on innovative products, services or technologies with the potential to have a significant impact on future sustainability and health.

Selected High-tech
life science portfolio companies

Selected High-tech
sustainability projects

Let's build better businesses together

Wlanholding – Dr. Werner Lanthaler
Schönborngasse 4, 1080 Vienna
office@wlanholding.com

Dr. Werner Lanthaler

Board Roles & Advisory Positions

Currently, Dr. Lanthaler serves as Chairman of the Board of Proxygen GmbH. He is also a board member of AC Immune AG (NASDAQ:ACI), Cerabyte GmbH and Soravia GmbH. Additionally, he acts as an Advisor to several Ven-ture and Private Equity Funds, including Forbion and Hevolution.

Leadership at Evotec SE (2009 – 2024)

As the CEO of Evotec SE (NASDAQ:EVO), a drug discovery and development company, Werner successfully led the company through various growth stag-es, expanding workforce from 200 to over 5,000 employees and revenues from € 40 m to € 800 m. Until he stepped down form his role in 2024, he was responsible for driving several world leading innovation initiatives e.g., drug discovery with iPS cells, Omics-driven drug discovery, and fully continuous manufacturing for biologics.

CFO at Intercell AG (2000 – 2009)

Before his time at Evotec, Werner was the CFO of Intercell AG, where he was instrumental in establishing Austria’s first venture-backed biotech company, overseeing the first IPO of an Austrian Biotech and the global launch of a Jap-anese Encephalitis vaccine.

Earlier Career & Education

Before joining Intercell, Werner held the role of Senior Vice President of Or-ganization, Finance, Marketing & Communications at the “Industriellen-vereinigung” (Federation of Austrian Industry) in Vienna. Earlier in his ca-reer, after earning a MPA (Master of Public Administration) from Havard University (J.F Kennedy School of Government), he worked for McKinsey & Company across offices in Boston, Düsseldorf, and Vienna.

Academic Background and Publications

Werner holds a PhD in Business from the Vienna University of Economics and Business (Wirtschaftsuniversität Wien), and has additional degrees in Busi-ness, Project Management, and Psychology. He is also the author of serval books and articles.